Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 12/20 | 0.44 |
| ▸ | GSK3B | P49841 | 7/20 | 0.44 |
| ▸ | WNT1 | P04628 | 3/20 | 0.44 |
| ▸ | LPL | P06858 | 5/20 | 0.43 |
| ▸ | LIPG | Q9Y5X9 | 5/20 | 0.43 |
| ▸ | CLK2 | P49760 | 2/20 | 0.41 |
| ▸ | CLK3 | P49761 | 2/20 | 0.41 |
| ▸ | MET | P08581 | 2/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17113470 | 0.91 | LIPG (0.49) | DYRK1AGSK3BWNT1LPLLIPG | |
| SCHEMBL657486 | 0.85 | FFAR1 (0.44) | DYRK1AGSK3BWNT1CLK2CLK3 | |
| SCHEMBL17113554 | 0.84 | LPL (0.47) | LPLLIPG | |
| SCHEMBL15299291 | 0.79 | LIPG (0.56) | LPLLIPG | |
| SCHEMBL17113549 | 0.78 | JAK2 (0.47) | LPLLIPG | |
| SCHEMBL17129417 | 0.78 | JAK2 (0.47) | LPLLIPG | |
| SCHEMBL21426239 | 0.78 | FFAR1 (0.42) | DYRK1AGSK3BWNT1 | |
| SCHEMBL21588639 | 0.77 | FFAR1 (0.40) | DYRK1AGSK3BWNT1CLK2CLK3 | |
| SCHEMBL24643242 | 0.77 | LIPG (0.42) | LPLLIPG | |
| SCHEMBL31276806 | 0.77 | DYRK1A (0.47) | DYRK1AGSK3BWNT1CLK2CLK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4712969-A1 | CYCLIN INHIBITORS | Circle Pharma, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20240408169-A1 | CYCLIN INHIBITORS | CIRCLE PHARMA, INC. | 2024-12-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240408169-A1 | CYCLIN INHIBITORS | CCNI, CDK2, CDK1 | DYRK1A 3674/4885GSK3B 319/4885WNT1 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.